Compare Stocks

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$7.46 -1.2%	$9.72	$2.09 ▼ $14.84	$528.88M	0.05	5.57 million shs	1.69 million shs

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	-5.51%	-12.31%	-23.43%	-30.06%	+57.95%

Trump’s “Tax Free” Retirement Strategy (Ad)

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	1.4035 of 5 stars	3.3	2.0	0.0	0.0	2.6	1.7	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.67	Moderate Buy	$15.00	101.61% Upside

Current Analyst Ratings

Latest ALT, POLX, and AZV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/1/2024	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
3/28/2024	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
2/13/2024	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
1/24/2024	ALT Altimmune	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$13.00

(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$426K	1,238.17	N/A	N/A	$2.75 per share	2.71

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.45M	-$1.65	N/A	N/A	N/A	-20,780.75%	-44.77%	-40.72%	5/9/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	17.26	17.26

Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	52	70.90 million	67.99 million	Optionable

ADR, ALT, and HMD Headlines

Source	Headline
	Altimmune (NASDAQ:ALT) Shares Down 7% marketbeat.com - April 15 at 5:31 PM
	Buy Altimmune's Potential Market Disruption With Pemvidutide seekingalpha.com - April 12 at 1:10 PM
	3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 investorplace.com - April 11 at 12:24 PM
	Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead. fool.com - April 9 at 6:45 AM
	Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? marketbeat.com - April 9 at 6:08 AM
	Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? marketbeat.com - April 9 at 6:07 AM
	Altimmune (NASDAQ:ALT) Shares Down 5.2% marketbeat.com - April 8 at 11:59 AM
	Timelo Investment Management Inc. Grows Stock Position in Altimmune, Inc. (NASDAQ:ALT) marketbeat.com - April 6 at 6:39 PM
	HC Wainwright Weighs in on Altimmune, Inc.'s Q1 2024 Earnings (NASDAQ:ALT) marketbeat.com - April 4 at 8:48 AM
	Altimmune (NASDAQ:ALT) Stock Price Down 8.1% After Analyst Downgrade marketbeat.com - April 2 at 10:27 AM
	The 3 Best Biotech Stocks to Buy in April 2024 investorplace.com - April 1 at 9:09 PM
	Altimmune’s Pemvidutide Shows Promise for Obesity Treatment, Justifying Buy Rating markets.businessinsider.com - April 1 at 8:08 PM
	Altimmune (NASDAQ:ALT) Price Target Lowered to $12.00 at HC Wainwright marketbeat.com - April 1 at 1:38 PM
	Eli Lilly: Three Threats To Its Huge Rally seekingalpha.com - March 31 at 4:34 PM
	A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drug msn.com - March 29 at 2:45 PM
	Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade zacks.com - March 29 at 1:01 PM
	Altimmune, Inc. (NASDAQ:ALT) Forecasted to Post Q1 2024 Earnings of ($0.30) Per Share marketbeat.com - March 29 at 8:16 AM
	Ad Campaign for Weight-Loss Drugs Reinforces Proper Use medscape.com - March 29 at 4:44 AM
	Altimmune (NASDAQ:ALT) Shares Up 5.3% marketbeat.com - March 28 at 3:46 PM
	Altimmune boasts of differentiated obesity option thepharmaletter.com - March 28 at 1:41 PM
	Altimmune Axes Hepatitis B Program After Phase II Failure, Focuses on Obesity and MASH biospace.com - March 28 at 1:41 PM
	Altimmune (NASDAQ:ALT) Receives "Buy" Rating from B. Riley marketbeat.com - March 28 at 12:33 PM
	Altimmune, Inc. (NASDAQ:ALT) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 28 at 11:06 AM
	Altimmune says weight loss drug minimized muscle loss in trial results, which may set it apart msn.com - March 28 at 8:41 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Stocks With Unusual Call Option Activity
March 26, 2024 1:10 PM
View 3 Stocks With Unusual Call Option Activity
Top 3 Stocks Bought By Members of Congress In the First Quarter
March 25, 2024 8:55 AM
View Top 3 Stocks Bought By Members of Congress In the First Quarter
3M Spun Off Its Health Division, Is It Still A Buy?
April 4, 2024 7:47 AM
View 3M Spun Off Its Health Division, Is It Still A Buy?
4 Dividend Aristocrats Trading at a Discount
April 1, 2024 6:10 AM
View 4 Dividend Aristocrats Trading at a Discount
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
April 9, 2024 6:07 AM
View Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?

All Headlines

Company Descriptions

Altimmune

NASDAQ:ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial